
Ask a doctor about a prescription for ALMOTRIPTAN VIATRIS 12.5 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Almotriptan Viatris 12.5 mg film-coated tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
Almotriptan Viatris contains almotriptan, an antimigraine medication belonging to a class of compounds known as selective serotonin receptor agonists (also known as "triptans"). Almotriptan is believed to reduce the inflammatory response associated with migraines by binding to serotonin receptors in cerebral blood vessels (cranial), causing vasoconstriction.
Almotriptan is used to relieve headache pain associated with migraine attacks with or without aura.
Do not take Almotriptan Viatris
Warnings and precautions
Consult your doctor or pharmacist before starting to take Almotriptan Viatris if:
During treatment
It has been suggested that excessive use of antimigraine medications may lead to chronic headache.
Children and adolescents
Children under 18 years old should not take almotriptan.
Elderly patients (over 65 years old)
If you are over 65 years old, you should consult your doctor before taking this medicine.
Using Almotriptan Viatris with other medicines
Tell your doctor or pharmacist that you are taking, have recently taken, or might take any other medicines.
Tell your doctor:
After taking almotriptan, it is recommended to wait at least 6 hours before taking ergotamine (a medication for treating migraine attacks).
After taking ergotamine, it is recommended to wait at least 24 hours before taking almotriptan.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Only limited information is available on the use of almotriptan during pregnancy.
Pregnancy: Almotriptan should only be used during pregnancy if prescribed by your doctor and only after carefully considering the risks and benefits.
Breastfeeding: Caution should be exercised when using this medicine during breastfeeding. You should avoid breastfeeding during the 24 hours following treatment.
Ask your doctor or pharmacist for advice before taking any medicine.
Driving and using machines
Almotriptan or migraine may cause drowsiness. If you experience drowsiness, do not drive or operate machinery or tools.
Almotriptan Viatris contains sodium
This medicine contains less than 1mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Follow the instructions for administration of this medicine exactly as indicated by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again. Almotriptan should only be used to treat an ongoing migraine attack and not to prevent migraine attacks or headaches.
The tablets should be swallowed with liquid (e.g., water) and can be taken with or without food.
Adults (18 - 65 years old)
Patient with severe renal impairment
If you have severe kidney disease, do not take more than one 12.5 mg tablet in 24 hours.
If you take more Almotriptan Viatris than you should
If you accidentally take too many tablets, or if someone else or a child takes this medicine, consult your doctor or pharmacist immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount ingested.
If you forget to take Almotriptan Viatris
Try to take Almotriptan Viatris as prescribed. Do not take a double dose to make up for forgotten doses.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you notice any of the following side effects, stop taking this medicine and consult your doctor or go to the emergency department of your nearest hospital immediately:
Very rare (may affect up to 1 in 10,000 people)
Frequency not known (cannot be estimated from the available data):
Tell your doctor immediately if you experience:
Other possible side effects
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Very rare (may affect up to 1 in 10,000 people):
Not known (cannot be estimated from the available data):
Reporting of side effects:
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and the carton after EXP. The expiry date is the last day of the month shown.
No special storage conditions are required.
Medicines should not be disposed of via wastewater or household waste. Return the blisters and any unused medicine to a pharmacy for disposal. If you are unsure, ask your pharmacist how to dispose of blisters and any unused medicine. This will help protect the environment.
Composition of Almotriptan Viatris
Appearance of Almotriptan Viatris and contents of the pack
Almotriptan Viatris are white or almost white, round, biconvex tablets, marked with "M" on one side and "AL2" on the other.
Almotriptan Viatris tablets are packaged in blisters of 3, 4, 6, 9, and 12.
Almotriptan Viatris tablets are packaged in single-dose perforated blisters of 4 and 6.
Not all pack sizes may be marketed.
Marketing authorisation holder
Viatris Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
Manufacturer(s)
McDermott Laboratories Ltd t/a Gerard Laboratories
35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13
Ireland
Or
Mylan Hungary Kft.
Mylan utca 1., Komárom, 2900
Hungary
You can request more information about this medicine by contacting the local representative of the marketing authorisation holder:
Viatris Pharmaceuticals, S.L.U.
C/ General Aranaz, 86
28027 - Madrid
Spain
This medicine is authorised in the Member States of the European Economic Area under the following names:
Spain - Almotriptan Viatris 12.5 mg film-coated tablets EFG
France - ALMOTRIPTAN VIATRIS 12.5 mg, film-coated tablet
Italy - Almotriptan MYLAN
Date of last revision of this leaflet:November 2020
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of ALMOTRIPTAN VIATRIS 12.5 mg FILM-COATED TABLETS in November, 2025 is around 19.53 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for ALMOTRIPTAN VIATRIS 12.5 mg FILM-COATED TABLETS – subject to medical assessment and local rules.